This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Diagnosed with heterozygous familial hypercholesterolemia
Adult between 18 and 50 years old
LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion
Renal insufficiency, defined as eGFR < 30 ml/min
History of atherosclerotic cardiovascular events
Atrial fibrillation
Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator